Who is sponsoring NCT04903197?

NCT04903197 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT04903197?

Interventions in NCT04903197: VAY736, lenalidomide.

Is NCT04903197 still recruiting?

NCT04903197 is currently terminated. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT04903197

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Terminated Phase 1 Last updated 1 April 2026

What this trial tests

Phase 1 trial testing VAY736 in Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma in 18 participants. Terminated before completion.

Timeline

24 January 2022

Primary endpoint
24 February 2025

24 February 2025

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	24 January 2022
Primary completion	24 February 2025
Estimated completion	24 February 2025
Sites	10 locations across Italy, Japan, Germany, South Korea, Australia, China, Singapore

Drugs / interventions tested

VAY736 — full drug profile →
lenalidomide — full drug profile →

Conditions studied

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma — all drugs for Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

NF-κB signaling in inflammation and cancer.
Zhang T, Ma C, Zhang Z, Zhang H, et al · · 2021 · cited 386× · PMID 34977871 · DOI 10.1002/mco2.104
Inflammation in cancer: therapeutic opportunities from new insights.
Xie Y, Liu F, Wu Y, Zhu Y, et al · · 2025 · cited 53× · PMID 39994787 · DOI 10.1186/s12943-025-02243-8
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy.
Beer SA, Went M, Mills C, Wood C, et al · · 2025 · cited 5× · PMID 40199857 · DOI 10.1038/s41408-025-01277-x

Verify or expand the search:

Other trials of VAY736

Trials testing the same drug.

NCT05349214 — Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome · Phase 3 · active not recruiting
NCT05350072 — Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome · Phase 3 · active not recruiting
NCT03827798 — Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 2 · active not recruiting
NCT03656562 — Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients · Phase 2 · completed
NCT03400176 — VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib · Phase 1 · terminated

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04903197 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04903197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing